Polomar Health Services, Inc. reported a significant revenue increase to $3.74 million for the nine months ended September 30, 2026, compared to just $16,174 in the prior year period. Despite this growth, the company incurred a net loss of $829,002 and maintains a stockholders' deficit of $2.84 million, though it achieved positive cash flow from operations of $193,996.
Polomar Health Services Debt Financing Update with Island 40 Group, LLC
Polomar Health Services executed a $450,000 promissory note and loan agreement with Island 40 Group, LLC to settle outstanding commissions owed for sales and distribution services. The note bears an initial 10% interest rate and is guaranteed by the company's wholly owned subsidiary, Polomar Specialty Pharmacy, LLC. The debt matures on March 31, 2027, and represents the formalization of a direct financial obligation for past services.
Polomar Health Services announced that its financial statements for the first and second quarters of 2026 can no longer be relied upon due to accounting errors. The company identified unrecorded expenses, revenue recognition issues, and the misclassification of preferred stock, which are expected to increase its aggregate net loss by approximately $421,000. Polomar intends to restate these periods and expects to report one or more material weaknesses in its internal controls.
Alexandra Peterson and Gabrielle Toledano resigned from the Board of Directors of Polomar Health Services, Inc., effective October 14, 2026. Following these departures, the Board reduced its size from five to three directors. The company stated the resignations were not due to any disagreements regarding operations, policies, or practices.